Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...

Depolarizing Blockers: Pharmocokinetics

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Skeletal Muscle Relaxants: Adverse Effects

Skeletal Muscle Relaxants: Adverse Effects

Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part I: A Review of the Pharmacokinetic Literature and Proposed Changes.

Journal of clinical psychopharmacology·2025

Same author

Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II: A Review of Fatal Outcomes in US Pharmacovigilance Data and Proposed Changes.

Journal of clinical psychopharmacology·2025

Same author

Pharmacokinetic and pharmacodynamic considerations with psychiatric disorders and migraines.

The mental health clinician·2024

Same author

Med rec double check: Inpatient psychiatry medication errors identified on admission using Medicaid Web portals and electronic pharmaceutical claims data.

The mental health clinician·2024

Same author

A Comment on the Midlevel Care Provider System in New York State.

The primary care companion for CNS disorders·2023

Same author

Escaping the Long Shadow Cast by Agranulocytosis: Reflections on Clozapine Pharmacovigilance Focused on the United Kingdom.

Journal of clinical psychopharmacology·2023

Search research articles

Related Experiment Video

Updated: Apr 16, 2026

Establishment of a Mouse Model with Cough Hypersensitivity via Inhalation of Citric Acid

Establishment of a Mouse Model with Cough Hypersensitivity via Inhalation of Citric Acid

Published on: January 10, 2025

Donepezil-related intractable hiccups: a case report.

Ian R McGrane¹, Michael D Shuman, Robert W McDonald

¹Department of Pharmacy, Providence St. Joseph Medical Center, Polson, Montana.

Pharmacotherapy

|March 11, 2015

Summary

Donepezil, a medication for Alzheimer's disease, may cause intractable hiccups. Reducing or stopping the drug resolved the patient's persistent hiccups, suggesting a causal link.

Keywords:

adverse drug event cholinesterase inhibitors donepezil drug therapy hiccough hiccup intractable hiccup respiratory disease singultus

More Related Videos

Full-Endoscopic Surgery for Hypothalamic Hamartoma Resection

Full-Endoscopic Surgery for Hypothalamic Hamartoma Resection

Published on: April 12, 2024

Robotic Myotomy and Partial Fundoplication for Achalasia

Robotic Myotomy and Partial Fundoplication for Achalasia

Published on: August 11, 2023

Related Experiment Videos

Last Updated: Apr 16, 2026

Establishment of a Mouse Model with Cough Hypersensitivity via Inhalation of Citric Acid

Establishment of a Mouse Model with Cough Hypersensitivity via Inhalation of Citric Acid

Published on: January 10, 2025

Full-Endoscopic Surgery for Hypothalamic Hamartoma Resection

Full-Endoscopic Surgery for Hypothalamic Hamartoma Resection

Published on: April 12, 2024

Robotic Myotomy and Partial Fundoplication for Achalasia

Robotic Myotomy and Partial Fundoplication for Achalasia

Published on: August 11, 2023

Area of Science:

Neurology
Pharmacology

Background:

Intractable hiccups can be a debilitating condition with various potential causes.
Donepezil is a centrally acting acetylcholinesterase inhibitor commonly used in Alzheimer's disease treatment.

Observation:

A case report details a patient experiencing intractable hiccups.
The patient's hiccups were unresponsive to standard treatments.
Symptoms resolved upon dose reduction and discontinuation of donepezil.

Findings:

The patient experienced recurrent episodes of intractable hiccups.
Hiccup onset was associated with donepezil initiation on three occasions.
Hiccup resolution occurred upon donepezil discontinuation on two occasions.

Implications:

This case suggests a potential association between donepezil and intractable hiccups.
It highlights the importance of considering centrally acting medications in the differential diagnosis of persistent hiccups.
Further investigation into drug-induced hiccups related to acetylcholinesterase inhibitors may be warranted.